Quantcast

A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis.

Research paper by Thomas T Schwarz, Inga I Kreiselmaier, Thomas T Bieber, Diamant D Thaci, Jan C JC Simon, Michael M Meurer, Thomas T Werfel, Torsten T Zuberbier, Thomas A TA Luger, Andreas A Wollenberg, Matthias M Bräutigam

Indexed on: 09 May '08Published on: 09 May '08Published in: Journal of The American Academy of Dermatology



Abstract

Perioral dermatitis (POD) is a common dermatosis without standard therapy.We sought to evaluate pimecrolimus cream 1% in POD.We conducted a multicenter, randomized, double-blind, parallel-group study in adult patients with POD treated twice daily with pimecrolimus cream 1% or vehicle until clearance for up to 4 weeks. Follow-up took place 4 and 8 weeks after treatment.Patients treated with pimecrolimus had an average POD Severity Index score of 2.6 compared with 3.5 for patients treated with vehicle. Both groups had baseline scores of 5.2. The between-group difference was 0.9 (95% confidence level 0.4, 1.4, P = .0011). Patients with history of topical corticosteroids benefited most. Pimecrolimus-treated patients reported greater improvement in quality of life. There were no group differences regarding safety.Pimecrolimus vehicle is not a true placebo.Pimecrolimus rapidly improves clinical symptoms and quality of life of patients with POD, being most effective in corticosteroid-induced POD.